Report highlights global biopharma interest in China

Ninety percent of global biopharma companies are interested in expanding to Asia, with 86% citing China specifically, according to a report from L.E.K. Consulting and BIO unveiled on Monday. Of the 88 biopharma executives surveyed, 92% said interest in China was driven by the country's expanding market, with many respondents also citing recent regulatory reforms as a factor.

But only 22% of those surveyed said China is their company’s top priority for expansion. Most U.S. companies prioritize Europe as their second market after establishing their home presence, and vice versa. Challenges still remain for entering China and Asia, including IP protections and adherence to different compliance policies, according to the report...